149 related articles for article (PubMed ID: 10742535)
1. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.
Nishizawa M; Nakabayashi H; Kawai K; Ito T; Kawakami S; Nakagawa A; Niijima A; Uchida K
J Auton Nerv Syst; 2000 Apr; 80(1-2):14-21. PubMed ID: 10742535
[TBL] [Abstract][Full Text] [Related]
2. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.
Nakabayashi H; Nishizawa M; Nakagawa A; Takeda R; Niijima A
Am J Physiol; 1996 Nov; 271(5 Pt 1):E808-13. PubMed ID: 8944665
[TBL] [Abstract][Full Text] [Related]
3. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein.
Nishizawa M; Nakabayashi H; Uchida K; Nakagawa A; Niijima A
J Auton Nerv Syst; 1996 Nov; 61(2):149-54. PubMed ID: 8946334
[TBL] [Abstract][Full Text] [Related]
4. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
Bucinskaite V; Tolessa T; Pedersen J; Rydqvist B; Zerihun L; Holst JJ; Hellström PM
Neurogastroenterol Motil; 2009 Sep; 21(9):978-e78. PubMed ID: 19453518
[TBL] [Abstract][Full Text] [Related]
5. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
6. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways.
Nishizawa M; Nakabayashi H; Uehara K; Nakagawa A; Uchida K; Koya D
Am J Physiol Endocrinol Metab; 2013 Aug; 305(3):E376-87. PubMed ID: 23715725
[TBL] [Abstract][Full Text] [Related]
7. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.
Hayes MR; Kanoski SE; De Jonghe BC; Leichner TM; Alhadeff AL; Fortin SM; Arnold M; Langhans W; Grill HJ
Am J Physiol Regul Integr Comp Physiol; 2011 Nov; 301(5):R1479-85. PubMed ID: 21849636
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
9. Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.
Marie JC; Boissard C; Skoglund G; Rosselin G; Breant B
Endocrinology; 1996 Oct; 137(10):4108-14. PubMed ID: 8828464
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
11. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
[TBL] [Abstract][Full Text] [Related]
12. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
Fehmann HC; Jiang J; Schweinfurth J; Wheeler MB; Boyd AE; Göke B
Peptides; 1994; 15(3):453-6. PubMed ID: 7937318
[TBL] [Abstract][Full Text] [Related]
13. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.
Navarro M; Rodriquez de Fonseca F; Alvarez E; Chowen JA; Zueco JA; Gomez R; Eng J; Blázquez E
J Neurochem; 1996 Nov; 67(5):1982-91. PubMed ID: 8863504
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Vahl TP; Tauchi M; Durler TS; Elfers EE; Fernandes TM; Bitner RD; Ellis KS; Woods SC; Seeley RJ; Herman JP; D'Alessio DA
Endocrinology; 2007 Oct; 148(10):4965-73. PubMed ID: 17584962
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.
Imeryüz N; Yeğen BC; Bozkurt A; Coşkun T; Villanueva-Peñacarrillo ML; Ulusoy NB
Am J Physiol; 1997 Oct; 273(4):G920-7. PubMed ID: 9357836
[TBL] [Abstract][Full Text] [Related]
16. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
17. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.
Barragán JM; Eng J; Rodríguez R; Blázquez E
Am J Physiol; 1999 Nov; 277(5):E784-91. PubMed ID: 10567003
[TBL] [Abstract][Full Text] [Related]
18. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors.
Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F
Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
Alcántara AI; Morales M; Delgado E; López-Delgado MI; Clemente F; Luque MA; Malaisse WJ; Valverde I; Villanueva-Peñacarrillo ML
Arch Biochem Biophys; 1997 May; 341(1):1-7. PubMed ID: 9143346
[TBL] [Abstract][Full Text] [Related]
20. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
Barragán JM; Rodríguez RE; Eng J; Blázquez E
Regul Pept; 1996 Nov; 67(1):63-8. PubMed ID: 8952007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
